1 / 4

ECS versus DES: TRIAS-HR 1 year

ECS versus DES: TRIAS-HR 1 year.

kyra-cline
Download Presentation

ECS versus DES: TRIAS-HR 1 year

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ECS versus DES: TRIAS-HR 1 year Objective: to demonstrate non-inferiority of endothelialprogenitorcellcapturingstents(ECS) versus drugelutingstents (DES)Study: multicenter, randomizedstudyPopulation: patients with PCI of at least 1 targetlesionat high-risk of restenosis(smallvessel ≤ 2,8mm, lesionlength ≥ 20mm, CTO or lesion in DM patient)Endpoint: TLF and MACE: Cardiacdeath, MI or TLR

  2. ECS versus DES: TRIAS-HR 1 year

  3. ECS versus DES: TRIAS-HR 1 year

  4. ECS versus DES: TRIAS-HR 1 year Conclusion ECS was not able to competewith DES in terms of restenosispreventionafter PCI of high-riskrestenosislesions Klomp JACC Interv 2011;4:896-904

More Related